NCT06422936 - Clinical Trial to Evaluate BO-112 in Patients with Basal Cell Carcinoma (BCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 27, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions

Basal Cell Carcinoma

Interventions

DRUG

BO-112

Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection

Trial Locations (10)

28027

NOT_YET_RECRUITING

Clínica Universitaria de Navarra (CUN), Madrid

37007

NOT_YET_RECRUITING

Complejo Asistencial Universitario de Salamanca, Salamanca

46009

NOT_YET_RECRUITING

Instituto Valenciano de Oncología (IVO), Valencia

48013

RECRUITING

Hospital de Basurto, Bilbao

7661041

RECRUITING

Kaplan Medical Center, Rehovot

Unknown

RECRUITING

Soroka Medical Center, Beersheba

RECRUITING

Rambam Medical Center, Haifa

RECRUITING

Hadassah Ein Kerem Medical Center, Jerusalem

RECRUITING

Sourasky Medical Center, Tel Aviv

08036

RECRUITING

Hospital Clínic Barcelona, Barcelona